FDA Clears Breztri for Asthma Use - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.

  • By

  • Kathryn Wighton

  • April 28, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of a new inhaled therapy for asthma maintenance treatment.

Approach:
    Key Findings:
    • Significant improvement in forced expiratory volume within 3 hours at 24 weeks.
    • Improvements in trough lung function over 12 to 24 weeks.
    • No new safety or tolerability concerns identified.
    Interpretation:

    The approval of Breztri addresses the needs of asthma patients who remain uncontrolled on dual therapies, potentially reducing exacerbations and improving daily breathing.

    Limitations:
    • Not intended for acute bronchospasm relief or as a substitute for rescue inhalers.
    • Limited to patients aged 12 years and older.
    Conclusion:

    Breztri offers a new maintenance treatment option for asthma, expanding its use beyond chronic obstructive pulmonary disease.

    Sources:

Original Source(s)

FDA Clears Breztri for Asthma Use

  • by Kathryn Wighton

  • April 28, 2026

Related Content

Case Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA—clinical lessons in eosinophil-targeted therapy

Does Pediatric Readiness Reduce ED Imaging?

Hospitals with stronger pediatric emergency capability used less imaging overall, but differences by insurance status and race and ethnicity remained.

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.